Video
Key Events in the FDA Pipeline During COVID-19
Pharmacy Times spoke with Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, about key events in the FDA pipeline, such as Emergency Use Authorizations during COVID-19 and the future of narrowed approvals.
Pharmacy Times spoke with Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, about key events in the FDA pipeline, such as Emergency Use Authorizations during COVID-19 and the future of narrowed approvals.
Landmon also discussed recent Emergency Use Authorizations that are crucial to highlight in the pipeline and the impact of "skinny labels" for generic products in the market.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
FDA Grants Full Approval to mRNA-1273 COVID-19 Vaccine in Children At Increased Risk
